Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells

Cisplatin is commonly used as a therapeutic agent, despite its known adverse side effects and the occurrence of drug resistance. The development of novel methods for combination therapy with cisplatin is required in order to circumvent these limitations of cisplatin alone. The proteasome inhibitor l...

Descripción completa

Detalles Bibliográficos
Autores principales: XU, YE, LI, DI, ZENG, LINCHUAN, WANG, CHUNYAN, ZHANG, LILI, WANG, YAN, YU, YANG, LIU, SHIBING, LI, ZHIXIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237085/
https://www.ncbi.nlm.nih.gov/pubmed/25323748
http://dx.doi.org/10.3892/mmr.2014.2683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237085/
https://www.ncbi.nlm.nih.gov/pubmed/25323748
http://dx.doi.org/10.3892/mmr.2014.2683

Ejemplares similares